CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 360 enrolled
Drug / intervention
Rabeprazole +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03320538
NCT03320538N/ACompleted

Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases: A Multicenter, Randomized, Double-blinded, Controlled Trial

Jiangxi University of Traditional Chinese Medicine·interventional·Posted Oct 25, 2017·Updated Jul 3, 2024

In Brief

A clinical study evaluating Hou Gu Mi Xi, Placebo, and 1 other intervention for Peptic Ulcer Disease. Completed, enrolled 360 participants across 1 site.

Detailed Summary

This trial aims to determine whether Jiangzhong Hou Gu® Mi Xi™ is an effective intervention to improve symptoms and indicators in patients with spleen qi deficiency and peptic ulcer diseases.

Study Details

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedOct 25, 2017
Enrollment StartJul 10, 2017
Primary CompletionSep 17, 2020
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.7 years ago

Interventions

Hou Gu Mi Xiother

Hou Gu Mi Xi is an oatmeal-liked, solid food (dry or dissolved eating).

Placeboother

The placebo is as same as Hou Gu Mi Xi in respect of color, taste, and smell.

Rabeprazoledrug

Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.